Dergiler / Anatolian Current Medical Journal / 2021 / Cilt: 3 - Sayı: 2

Evaluation of long-term effect of tuberculosis chemoprophylaxis in patients using anti tumor necrosis factor alpha agents

Sayfa
115–119
Yayın Tarihi
2021-04-24
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The mean number of neutrophiles and lymphocytes were significantly decreased after treatment(p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Introduction and Aim: There is an increased risk of tuberculosis (TB) in patients with rheumatoid diseases(RD) treated with anti TNF alpha agents.
📊
Temel Bulgular & Veri:Materials and Methods: Patients treated with anti TNF alpha agents for more than 5 years with RDs were evaluated retrospectively.
💡
Sonuç & Katkı:The mean number of neutrophiles and lymphocytes were significantly decreased after treatment(p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Anti TNF alpha · tuberculosis · chemoprophylaxis

Abstract

Introduction and Aim: There is an increased risk of tuberculosis (TB) in patients with rheumatoid diseases(RD) treated with anti TNF alpha agents. Screening and, if necessary, chemoprophylaxis is recommended in patients undergoing anti TNF alpha treatment. This study aimed to determine the incidence of active TB due to long term anti TNF alpha usage in patients with RD and to evaluate the effectiveness of tuberculosis chemoprophylaxis regimen. Materials and Methods: Patients treated with anti TNF alpha agents for more than 5 years with RDs were evaluated retrospectively. Demographic and clinical characteristics, use of chemoprophylaxis, laboratory tests before and after anti TNF alpha treatment and development of TB were examined. Results: A total of 150 patients (79 male [52.7%], 71 female [47.3%]) with a mean age of 45±13 years were evaluated. The tuberculosis rate over 5 years follow up was found as 1.3%. One male developed pulmonary TB 5 years and 1 female developed miliary TB 10 years after the beginning of anti-TNF alpha therapy despite chemoprophylaxis with isoniazid. The mean number of neutrophiles and lymphocytes were significantly decreased after treatment(p

🔖

Bu Makaleye Atıf Yap

BAŞLILAR, Ş., AYDIN, M. (2021). Evaluation of long-term effect of tuberculosis chemoprophylaxis in patients using anti tumor necrosis factor alpha agents. Anatolian Current Medical Journal, Cilt: 3 - Sayı: 2, 115–119. https://ajindex.com/articles/733836

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907– 15. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-9.
  2. Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol 2014; 41: S47‐S55. Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF‐α antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2017; 7: e012567. Nordgaard-Lassen I, Dahlerup JF, Belard E, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti TNF-alpha treatment. Dan Med J 2012; 59: 1-12.
  3. Kısacık B, Pamuk ON, Onat AM, et al. Characteristics predicting tuberculosis risk under tumor necrosis factor-α inhibitors: report from a large multicenter cohort with high background prevalence. J Rheumatol 2016; 43: 524-9.
  4. Doğan C, Kiral N, Comert SS, Fidan A, Caglayan B, Salepci B. Tuberculosis frequency in patients taking TNF alpha blockers. Turk Toraks Derg 2012; 13: 93-8.
  5. Aydın V, Akıcı A, Islı F, Aksoy M, Aydın M, Gürsöz H. Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study. J Clin Pharm Ther 2019; 44: 553-60. Sağlık Bakanlığı. Tüberküloz Tanı ve Tedavi Rehberi, 2. Baskı Ankara, Mayıs 2019. pp. 5-6.
  6. Hanta I, Ozbek S, Kuleci S, Kocabas A. The evaluation of latent tuberculosis in rheumatologic diseases for anti TNF Therapy: Experience with 192 patients. Clin Rheumatol 2008; 27: 1083-6.
  7. Chan MJ, Wen YH, Huang YB, et al. Risk of tuberculosis comparison in new users of antitumour necrosis factor‐α and with existing disease‐modifying antirheumatic drug therapy. J Clin Pharm Ther 2018; 43: 256-64.
  8. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52: 1986-92. Gomez‐Reino JJ, Carmona L, Angel DM. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-61. WHO. Global Tuberculosis Report 2017.
  9. Geneva, Switzerland: World Health Organizati